Background Image

Adnos™ - Alzheimer’s disease diagnostic device

an ultra-sensitive point-of-care diagnostic for detection of AD biomarkers


Adnos™ detects a generally accepted panel of AD-associated protein biomarkers by binding them to their corresponding antibody, such as Amyloid beta protein to Anti-beta amyloid antibody. Adnos sensor is being designed to detect AD biomarkers in cerebrospinal fluid (CSF) samples with minimally skilled personnel. Adnos is capable of detecting AD onset and monitoring progress in therapy.

Technological Benefits

Adnos is a simple, biosensor device offering:

  • Minimal sample preparation time
  • Diagnostic specificity
  • Highly sensitive detection
  • Disposable chip
  • Diagnosis under 30 minutes
  • Early diagnosis and therapy monitoring


  • Portable system
  • Cell phone/tablet compatible
  • Capable of multi-analyte detection
  • Compatible with CSF, blood, saliva and urine
  • Requires minimal skills to operate
  • Low power requirements

Potential Applications

  • Diagnostics, prognostics and theranostics
  • Point-of-care at a patient's bedside
  • As a tool for effective therapy management